CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Pfizer [NYSE:PFE]

Jeffrey Keisling, CIO & SVP

Formula Five for Biotech IT

Jeffrey Keisling

With the explosive growth of genomics data and the broad implementation of electronic medical records, there are more opportunities than ever to leverage technology to better serve the needs of patients. Healthcare, our understanding of disease, and our ability to positively impact patient health are all undergoing a transformational change. To this end, Pfizer’s Business Technology (BT) team has developed the “Formula Five”-five key strategies through which innovative technology solutions are deployed to enable success in biotechnology IT.


1. Medical and Clinical Science Goes to the Cloud


For decades, Pfizer has partnered with thousands of medical and clinical experts to conduct tens of thousands of clinical trials with hundreds of thousands of patients in hundreds of countries. More recently, the sources of medical knowledge has grown at an exponential rate, generating data measured in the petabytes–including tens of billions of data points with inputs from digital medical outcomes in the millions and vast amounts of genetic (DNA) information.


Pfizer’s focus on developing medicines to meet the toughest medical challenges–such as cancer, heart disease, neurological disorders, and Alzheimer’s disease–drives the need to sort through this complexity and focus on the meaningful data points. To that end, Business Technology has developed a scalable cloud architecture leveraging best-in-class agile technologies for clinical data management and analytics. This first-of-its-kind solution stores, annotates, integrates, and provides seamless access to useful data for scientists–enabling them to look for relationships between drug response and genotypes, identify extreme responders, and identify potential causal gene variants that may lead to additional ways to regulate a biological pathway.


2. Precision Medicine─Analytics Can Help Identify the Right Medicines for the Right Patients


Why are certain therapies successful in broad populations of patients, but less effective in others? Advanced analytics, using massively large and complex datasets, is a critical scientific tool in answering this question–by finding a single variable amongst billions of data points.


Leveraging advanced analytics and integrating anonymized information from clinical trials, biological networks, human genetics, pharmacology, toxicology and imaging, Pfizer has developed an innovative precision medicine approach that can now define and compare different methods of developing and delivering possible new medications in an effort to help address unmet medical needs.


Specifically, these advanced analytics enable Pfizer researchers to assess exploratory biomarkers to understand which patient subpopulations are most likely to benefit from an investigational therapeutic. Pfizer’s clinicians can then include such identified sub-populations in the clinical testing of potential new therapeutics. As DNA sequencing, imaging and other technologies have rapidly evolved and grown less expensive, Pfizer’s knowledge of human biology is also growing. The ability to access and use this information in a meaningful manner is essential to speeding the discovery and development of potential therapies for patients in need.


3. Digital and IoT Serving Patients and Physicians


Pfizer is at the forefront of embracing emerging technologies, open source, cloud computing and advanced interactive digital technologies to engage patients and physicians in a meaningful way that goes “beyond the pill” to provide better outcomes. Whether it is in leveraging mobile devices and novel apps to improve clinical trial data collection or in providing custom wearables to track pain levels to assist with physician conversations on dosing, Pfizer is focused on having insights drive the most meaningful features and utilizing technologies that are fit for purpose.


Business Technology has developed a scalable cloud architecture leveraging best-in-class agile technologies for clinical data management and analytics


An example is how Pfizer is partnering with the American Lung Association on a mission to support smokers’ attempts at a healthier life by utilizing technology to overcome common barriers to a successful quit attempt. The Quitters Circle combines a mobile app, a wearable, and a rich social media experience to provide quitters and their targeted support network with the tools they need to quit “for good”, including tracking tools, informative content, support triggers, Quitspiration, and ready access to physicians and telemedicine. Pfizer understands that the world we live in and the technologies at our fingertips are ever evolving, and through the creation of Pfizer’s Digital, Mobile, and Emerging Technologies Centers of Excellence, Pfizer has committed to ensuring their organization will as well.


Finally, Pfizer has begun using actigraphy data–data generated from sensors–to understand patient response to medicines. In effect, the “internet of things” becomes the “internet of patients” as FitBit-like sensors are used in our trials to continuously monitor patients to understand if Pfizer’s medicine is controlling their tremors, or if they are able to sleep at night. This type of data allows Pfizer to demonstrate an improvement in a patient’s quality of life in a way that wasn’t possible with traditional measurement models.


4. Partnering for Innovation─Bringing the Best Medical and Scientific Minds Together


Pfizer engages in hundreds of formal partnerships, actively building and cultivating relationships with top centers of medical and scientific innovation in academia, clinical, medical, and hospital institutions around the globe. Solving the world’s toughest medical challenges requires the ability to quickly and securely collaborate with these partners–crucial for advancing the development of innovative patient therapies while protecting Pfizer's intellectual property.


Business Technology plays a key role in enabling Pfizer's open innovation model through the use of scalable, agile and secure collaboration technologies. With sophisticated technology playbooks, processes and tools at their fingertips, it is now possible to establish secure connectivity and collaboration environments regardless of deal complexity in a matter of hours, rather than days or months, making Pfizer a respected “Partner of Choice”.


5. Thought Leadership in Business Technology


Because technology is embedded and acknowledged in every facet of science and business operations, Business Technology colleagues are accountable for demonstrating effective thought leadership–now a critical capability and a key factor in talent selection and advancement. Through effective thought leadership, successful IT organizations are identified as having more than just a "seat at the table”–but as being “front and center” in every facet of our business.


The Formula Five is a major driving force toward achieving Pfizer’s mission. The effective use of the clinical cloud, precision analytics, digital and emerging technologies, agile and secure collaborations, and the thought leadership to effectively align and connect these focus areas to business strategy, will all work together toward success in Biotechnology at Pfizer.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cioviewpoint/formula-five-for-biotech-it-nwid-281.html